3D Medicines Diagnosis Raises CNY 1.5 Bn after Being Spun-off
3D Medicines Diagnosis announced the close of CNY 1.5 billion in its second equity financing. It is the second independent bankroll for the diagnostics business unit after the spin-off from the group. It raised USD 140 million on January 6, 2020.
CPE led the investment, participated by China Capital Investment Group, Jimin Kexin Pharmaceutical, Tsing Song Capital, Spinnotec VC, Haier Homecare, Ruiyi Investment and Lan Shang Capital. Lucion VC, Shandong Industrial Development Fund and Sangel VC as previous shareholders continue buying in.
The raised capital, according to Mr.Xiong Lei, the board and CEO, will support the research and development for precision medicines, equipment and test kits products – specifically including Next Generation Sequencing (NGS) assembly line and other molecule diagnosis devices, multiple In-vitro diagnostics (IVD) for precision diagnosis, AI-based automation pipelines and overseas business development.